Time BioVentures, a Los Angeles, CA-based early-stage life sciences venture firm, closed its first Fund, with $100m AUM.
Backed by a roster of biotech and healthcare luminaries, Time BioVentures I, LP, will finance innovations in medicine. Its initial investments include Neuralink, Elon Musk’s brain-computer interface startup, and Kling Biotherapeutics, an Amsterdam-based drug development company.
The firm’s general partners are former rockstar D.A. Wallach and accomplished drug developer Tim Wright, who pioneered multiple blockbuster drugs while at Pfizer and Novartis, where he led Global Pharma Development. Beyond pharma, Wright has served on the boards of numerous private and public biotechs and as an advisor to the Bill & Melinda Gates Foundation. Wallach, a musician discovered by Pharrell Williams, has been investing for over a decade in startups ranging from Spotify to SpaceX, with a specific focus on healthcare innovators including Beam Therapeutics and Devoted Health.
Time BioVentures advisors include Sean Parker, Nobel Prize winner Jim Allison, oncology pioneer Dr. Padmanee Sharma, and former Illumina Chairman and CEO Jay Flatley. Founding LPs in the fund include Chris Sacca, Ron Burkle, and Wildcat Partner Holdings.
